Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387139 | 0.92 | EGFR (0.42) | EGFRCAPN1FFAR1LTB4R | |
| SCHEMBL4384148 | 0.89 | EGFR (0.40) | EGFRCAPN1CLCN2TP53LTB4R | |
| SCHEMBL4380474 | 0.88 | DPP4 (0.39) | EGFRCAPN1DPP4DHODHFABP3 | |
| SCHEMBL4384888 | 0.86 | DPP4 (0.39) | EGFRCAPN1DPP4DHODHLTB4R | |
| SCHEMBL4381984 | 0.85 | EGFR (0.41) | EGFRCLCN2DHODHFABP3FABP4 | |
| SCHEMBL4386776 | 0.84 | EGFR (0.43) | EGFRCAPN1CLCN2POLBFABP3 | |
| SCHEMBL4384780 | 0.84 | CNR2 (0.40) | EGFRPOLBMAPT | |
| SCHEMBL4379642 | 0.84 | EGFR (0.37) | EGFRCLCN2TP53MAPT | |
| SCHEMBL4386982 | 0.83 | EGFR (0.40) | EGFRDHODHCD274POLBLTB4R | |
| SCHEMBL4387790 | 0.83 | KDM4E (0.38) | EGFRCAPN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | EGFR 624/4885CAPN1 1225/4885DPP4 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.